Biogen to hive off hemophilia business into new publicly traded company

3 May 2016
2019_biotech_test_vial_discovery_big

US biotech major Biogen (Nasdaq: BIIB) today revealed that it intends to spin off its hemophilia business as an independent, publicly traded company.

The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise. The spin-off, which has been approved by the board of directors, is planned to be completed by the end of 2016 or early 2017.

The possibility of a Biogen breakup has been discussed for some time, and the hemophilia unit could have been worth about $4.2 billion to $4.9 billion in a sale, Bloomberg Intelligence analyst Asthika Goonewardene wrote last month. The new company will be anchored by the drugs Eloctate [antihemophilic Factor (recombinant), Fc fusion protein] for hemophilia A and Alprolix (coagulation Factor IX [recombinant]) for hemophilia B, Biogen said, and which last year generated in $320 million and $235 million in sales, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology